[Reporter's View] What's fair for addressing unmet needs

Now, cancer therapy has entered a stage where a single option cannot explain it all. Previously, when cytotoxic chemotherapy was the center of treatment, the type of cancer was the core criterion for determining a treatment strategy.

However, the situation is different now. Even within the same cancer type, entirely different agents are selected based on biomarkers, and even the sequence of treatment and combination strategies varies. The structure has changed to the point where a single disease is effectively split into several different diseases.

This change is not a phenomenon limited to specific areas. Non-small cell lung cancer (NSCLC) treatment has been subdivided based on various genetic mutations, and the approach to colorectal cancer also varies depending on biomarker characteristics such as BRAF. Targeted-based therapy is also expanding in rare cancers like biliary tract cancer.

Even in diseases where options were limited in the past, the treatment strategy must be redesigned.

The problem is that this variation does not stop at simply increasing options but leads to an expansion of the treatment scope.

Treatments previously applied primarily to metastatic patients are gradually expanding to include patients with stages 1 to 3, the early-stage patient group. As neoadjuvant, adjuvant, maintenance, and combination therapies are discussed simultaneously, treatment is shifting toward a structure that starts earlier and lasts longer.

Of course, from the patient's perspective, the ideal scenario is to receive reimbursement for all possible treatments. If newly emerging agents can be used for more patients at an earlier stage, the opportunity for treatment expands. However, the fact that these changes are occurring simultaneously across multiple cancer types rather than in a specific disease presents another dilemma.

Each treatment expansion may be a valid choice. However, the story changes if the same trend is repeated across various cancer types. This is because it is realistically difficult to raise all areas at the same pace with limited resources. Ultimately, it becomes necessary to decide which area to invest more resources in first.

In this process, there is one point to be cautious of. The needs of other cancer types must not be ignored simply because discussions are active and voices are loud in a specific cancer type.

Unmet needs are not a concept confined to specific diseases. ​Unmet needs are presented in different forms across various cancer types. There is a possibility that while the necessity of one area is emphasized, the gaps in other areas may be relatively overshadowed.

Ultimately, the question is clear: "To what extent and by what criteria will we apply the increased treatment options?" Applying all treatments to all patients may be ideal, but it is not a realistically possible option. Therefore, a discussion is needed on what criteria will be used to set priorities.

More opportunities for patients are available due to advances in cancer treatment. However, consideration must also be given to how to distribute those opportunities and to striking a balance to prevent bias toward specific areas during that process. This is why we must reconsider the concept of unmet needs from a broader perspective.